
TARA Stock Forecast & Price Target
TARA Analyst Ratings
Bulls say
Protara Therapeutics Inc. has demonstrated an improvement in the efficacy of its lead therapy, TARA-002, evidenced by 100% durability and an 80% salvage rate upon re-induction as observed in the 6-month clinical data. Additionally, the Phase 2 trial results indicate significant improvements in liver health through the addition of intravenous choline chloride, showcasing its potential to mitigate intestinal failure-associated liver disease. These positive developments in clinical efficacy and safety, combined with the potential for competitive positioning in the market, support a bullish outlook for Protara Therapeutics's stock.
Bears say
Protara Therapeutics reported a net loss of $12.7 million, translating to a loss of $0.48 per share in the fourth quarter of 2024, which raises concerns about the company's financial health. Despite exhibiting promising early signals for TARA-002 in non-muscle invasive bladder cancer (NMIBC), the stock trades at a significant discount compared to peers, suggesting potential undervaluation amidst financial instability. The competitive landscape for NMIBC therapies and ongoing challenges related to the availability of choline for patients suffering from intestinal-failure associated liver disease (IFALD) may further hinder the company's growth prospects.
This aggregate rating is based on analysts' research of Protara Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
TARA Analyst Forecast & Price Prediction
Start investing in TARA
Order type
Buy in
Order amount
Est. shares
0 shares